EQS-News: Vycor Medical, Inc.: Vycor Medical Releases Financial Results for the Three and Six Months Ended June 30, 2026
Vycor Medical, Inc. (OTCQB: VYCO) reported revenue of $418.3k for the three months ended June 30, 2026, down 16% from 2025, and $876.8k for six months, down 6%. Vycor Medical (VBAS) revenue fell 17% (quarter) and 7% (six months). GAAP operating profit was $6.9k (quarter) and $52.7k (six months).
How this was made
The 30-second read
Why it matters
The earnings release is primarily a financial performance update: revenue declined year over year, international sales weakness is emphasized, and operating profit trends diverge between 3-month and 6-month periods.
Market read
Traders can reassess near-term risk for VYCO based on disclosed revenue contraction and operating profit trajectory, plus ongoing VBAS clinical publication momentum.
What to watch
The release emphasizes non-GAAP adjustments and clinical paper counts but does not disclose cash balance, liquidity, or forward guidance, which are often the key drivers for OTCQBs after earnings.
Background
Vycor Medical is an OTCQBs-listed medical device company with VBAS (ViewSite Brain Access System) and a development-stage NovaVision therapy program.
Ticker impact
Vycor reported Q2 and 6M ended June 30, 2026 results, including revenue declines and GAAP/non-GAAP operating profit changes.
Near-term trading bias likely neutral to slightly negative unless investors focus on the six-month GAAP operating profit improvement and ongoing VBAS clinical publication momentum.
Key disclosed datapoints are revenue down 16% (3M) and 6% (6M), with GAAP operating profit of $6.9k (3M) vs $51.1k and $52.7k (6M) vs $38.3k. The article provides no guidance or balance-sheet/cash runway details, limiting conviction on direction.
Market effects
Provides a datapoint on demand volatility for neurosurgical access systems, with international orders described as lumpy.
Highlights that the revenue decline is primarily from international markets for both the 3-month and 6-month periods.
Limited broader market relevance; mainly company-specific read-through for small-cap medical device investors.
Counterpoint
Investors may discount the international revenue weakness as quarter-to-quarter order timing and instead emphasize the six-month GAAP operating profit improvement and continued VBAS peer-reviewed publications.
Key entities
- issuerVycor Medical, Inc.
Reports financial results for the three and six months ended June 30, 2026, including VBAS revenue declines and operating profit changes.
- productViewSite Brain Access System (VBAS)
Primary revenue driver; article cites revenue declines and three new peer-reviewed studies published during 2026 to date.
- business_unitNovaVision
Development-stage division; article reports small revenue increases for the three and six months ended June 30, 2026.
